Catalog No.
Product Name
Application
Product Information
Citations
-
CB1R Allosteric Modulator
CB1R Allosteric Modulator 1 is a potent allosteric modulator targeting the cannabinoid receptor type 1 (CB1R). It functions as a negative allosteric modulator, inhibiting the activity of orthosteric ligands at CB1Rs. This compound is valuable for exploring the role of CB1R in various physiological processes and has potential applications in research related to neuropharmacology and therapeutic development for disorders influenced by the endocannabinoid system. -
CB1 Activator
AM841 is an electrophilic ligand that acts as a high-affinity activator of the CB1 cannabinoid receptor. By covalently binding to a cysteine residue in helix six, AM841 effectively reduces Forskolin-stimulated cAMP accumulation and has been shown to slow gastrointestinal motility. This compound is useful for research applications investigating cannabinoid receptor signaling and its physiological effects. -
CB1 Inverse agonist
TM38837 is a selective inverse agonist targeting cannabinoid receptor 1 (CB1), exhibiting an IC50 of 24 nM. With a significantly higher selectivity for CB1 over cannabinoid receptor 2 (CB2) (IC50: 4500 nM), TM38837 demonstrates potential in modulating metabolic processes. Its biological activity includes reducing body weight and improving plasma inflammatory markers and glucose homeostasis, making it a valuable tool for research on metabolic disorders and obesity. -
CB1R agonist
Δ9-THCB (Δ9-Tetrahydrocannabutol) is a potent agonist of the CB1 receptor, exhibiting a Ki value of 15 nM for human CB1 and 51 nM for CB2 receptors. This compound demonstrates significant analgesic and anti-inflammatory properties, making it a valuable tool for research focused on pain management and inflammation. Its partial agonistic effects on the CB1 receptor in in vivo models provide insights into cannabinoid receptor signaling and potential therapeutic applications. -
CB1/CB2 Agonist
Mead ethanolamide is an endogenous agonist of the cannabinoid receptors CB1 and CB2, exhibiting Kd values of 753 nM and 1810 nM, respectively. This compound plays a significant role in modulating cannabinoid receptor activity, making it a valuable tool for researching the endocannabinoid system's physiological and pharmacological effects. Its biological activity contributes to studies on pain management, neuroprotection, and various neurological disorders. -
Anandamide Transport Inhibitor
N-(3-Hydroxyphenyl)-arachidonoyl amide is an anandamide transport inhibitor, exhibiting an IC50 of 21.3 μM. This compound serves as a valuable tool in understanding endocannabinoid signaling and lipid metabolism. It can be utilized in research applications focusing on cannabinoid receptors and the modulation of neuronal activity. -
Anti-Analgesic Agent
Levonantradol hydrochloride is an analog of delta(9)-tetrahydrocannabinol that primarily functions as an anti-analgesic agent. It exhibits significant analgesic properties, making it valuable for research related to pain management and cannabinoid receptor studies. Its role in modulating pain pathways can aid in the development of novel therapeutic strategies for chronic pain conditions. -
CB2R Agonist
PM226 is a selective agonist of the cannabinoid receptor CB2 (Ki = 13 nM; EC50 = 39 nM) with minimal interaction with CB1 (Ki > 40 μM). This compound exhibits neuroprotective effects in both in vitro and in vivo studies, making it a valuable tool for research in neurodegenerative disorders. PM226 may also be applicable in exploring the therapeutic potential of cannabinoid receptors in various biological systems. -
Cannabinoid Receptor Antagonist
NIDA-41020 is a potent and selective antagonist of the cannabinoid receptor 1 (CB1), exhibiting a Ki value of 4.1 nM. This compound is designed for use as a radioligand in positron emission tomography (PET) studies. NIDA-41020 facilitates the investigation of CB1 receptor dynamics and its role in various biological processes, making it a valuable tool for cannabinoid research. -
Endocannabinoid
γ-Linolenoyl monoethanolamide is a fatty N-acyl ethanolamine that acts as an endocannabinoid. It is involved in modulating various physiological processes through cannabinoid receptor pathways. This compound has potential applications in research focused on pain management, inflammation, and neuroprotection, making it a valuable tool for exploring the endocannabinoid system in health and disease. -
CB1 Receptor Agonist
RVD-Hpα is a CB1 cannabinoid receptor agonist derived from an α-hemoglobin peptide with three additional amino acids. This compound acts as a positive allosteric modulator of cannabinoid receptor 2. RVD-Hpα is primarily utilized in research focused on the endocannabinoid system and its associated signaling pathways, making it valuable for studies exploring therapeutic effects related to cannabinoid receptors. -
CB1 receptor ligand
JHU-75528 is a selective ligand for the cannabinoid receptor CB1. This compound exhibits high affinity for the CB1 receptor, making it a valuable tool for studies involving cannabinoid signaling pathways. It is particularly useful in imaging research focused on the role of CB1 in various physiological and pathological processes. -
CB2R Antagonist
CB2R Antagonist 4 is a selective antagonist and inverse agonist of the cannabinoid receptor type 2 (CB2R) with a pKi of 6.54. This compound exhibits over 11-fold selectivity for CB2R when compared to CB1R, making it a valuable tool for research involving the endocannabinoid system. Its pharmacological properties allow for the exploration of CB2R's role in various neurological processes and disorders. -
CB-1 Receptor Antagonist
BMS-812204 is a selective antagonist of the cannabinoid receptor type 1 (CB-1). It demonstrates significant potential in research focused on obesity and metabolic disorders by modulating CB-1 signaling pathways. This compound serves as a valuable tool in elucidating the role of cannabinoid receptors in metabolic regulation and may aid in the development of therapeutic strategies for related conditions. -
CB1 Ligand
GAT228 is an allosteric ligand for cannabinoid receptor 1 (CB1). This compound modulates CB1 receptor activity, influencing cannabinoid signaling pathways. GAT228 is employed in research focused on cannabinoid system mechanisms, neuropharmacology, and potential therapeutic applications in pain management and metabolic disorders. -
CB1/2 Agonist
AB-FUBICA is a potent agonist for CB1 and CB2 receptors, serving as a valuable tool in cannabinoid research. It functions by activating G-protein coupled inwardly rectifying potassium channels (GIRK) through its binding to these receptors, demonstrating significant cannabinoid-like activity. With EC50 values of 21 nM for CB1 and 15 nM for CB2, AB-FUBICA is ideal for investigating pain management, neurodegenerative diseases, and inflammation-related pathways. -
Cannabinoid
FDU-PB-22 is a synthetic cannabinoid that primarily targets cannabinoid receptors. It is rapidly metabolized in human liver microsomes, exhibiting a half-life of 12.4 minutes. This compound is valuable for research applications involving cannabinoid receptor signaling and pharmacokinetics, enabling investigations into the effects of synthetic cannabinoids on physiological and neurological processes. -
CB1/CB2 Ligand
9β,10β-epoxy Hexahydrocannabinol is a selective ligand for the cannabinoid receptors CB1 and CB2, exhibiting binding affinities of 224 nM and 335 nM, respectively. This compound has demonstrated significant biological activities, including the reduction of locomotor activity, induction of catalepsy, and lowering of body temperature, along with antinociceptive effects in murine models. Its relevant pharmacological profile makes it a valuable tool for research focused on the mechanisms underlying nervous system diseases. -
Endocannabinoid Analog
AM11638 is an endocannabinoid analog that selectively targets cannabinoid receptors CB1 and CB2, demonstrating notable analgesic properties. This compound is valuable for investigating various neurological disorders and inflammation-related conditions, providing a platform for the development of therapeutic interventions in these areas. -
Multi-target modulator
PQM-244 is a multi-target modulator that primarily interacts with TRPV1 and cannabinoid receptors CB1 and CB2. It exhibits noteworthy peripheral antinociceptive properties, effectively addressing both neurogenic and inflammatory pain. Additionally, PQM-244 demonstrates antioxidant activity with an IC50 of 14.15 µM for radical scavenging of DPPH. This compound is suitable for research applications related to chronic pain and inflammatory conditions, including diabetes, atherosclerosis, and Alzheimer's disease. -
CB2 Inverse-Agonist
COR170 is a selective inverse agonist of the CB2 receptor, identified as a 4-quinolone-3-carboxylic acid derivative with a Ki value of 3.8 nM. This compound has shown potential in modulating inflammatory responses and provides insights into neuroprotective mechanisms. It is valuable for research applications focused on understanding the role of CB2 receptors in various biological processes related to inflammation and neuroprotection. -
CB1 Inhibitor
CB1-IN-2 is a selective CB1 receptor inhibitor, characterized by an IC50 of 0.644 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for studies exploring its potential central nervous system effects. CB1-IN-2 can be applied in research focused on cannabinoid receptor modulation and its implications in various neurological and psychological conditions. -
Cannabinoid Receptor Ligand
Pirnabine is a cannabinoid receptor ligand that selectively interacts with the CB1 and CB2 receptors. This compound has demonstrated potential in modulating intraocular pressure, making it relevant for glaucoma research. Investigating Pirnabine may provide insights into cannabinoid therapeutic strategies for ocular conditions. -
Cannabinoid
AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that selectively targets CB1 receptors in the central nervous system, demonstrating a binding affinity of Ki= 0.9 nM. This compound exhibits significant anticonvulsant activity, making it valuable for research related to epilepsy and other neurological disorders. Its role in modulating cannabinoid receptor activity offers potential insights into endocannabinoid system functions and therapeutic applications. -
CB1 Receptor Ligand
Prostaglandin E2-1-glyceryl ester serves as a selective ligand for the CB1 receptor, functioning as an important endocannabinoid modulator. This compound is known to induce a rapid and transient increase in intracellular free calcium concentrations, thus playing a vital role in signal transduction pathways. Its functionality makes it a valuable reagent for research investigating cannabinoid receptor dynamics and related physiological effects. -
CB1 Agonist
AM8936 is a potent and balanced agonist of the cannabinoid receptor type-1 (CB1), exhibiting EC50 values of 8.6 nM for rat CB1 (rCB1) and 1.4 nM for human CB1 (hCB1). With a high affinity for rCB1 demonstrated by a Ki of 0.55 nM, AM8936 is effective in vivo. This compound is instrumental in research related to central nervous system disorders, metabolic diseases, pain management, and glaucoma. -
Stable Isotope
N-Arachidonyldopamine-d8 is a deuterium-labeled derivative of N-Arachidonyldopamine. This stable isotope is utilized in metabolic studies, allowing for precise tracking of molecular interactions and pathways in biological systems. Its key applications include research in neurobiology and pharmacology, particularly in understanding endocannabinoid signaling and dopamine receptor interactions. -
Cannabinoid Receptor Antagonist
Hemopressin (rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, with its origins traced to rat brain homogenates. This compound serves as a selective inverse agonist of CB1 cannabinoid receptors, demonstrating oral bioactivity. Hemopressin (rat) TFA exhibits significant antinociceptive effects in models of inflammatory pain, making it a valuable tool for research in pain modulation and cannabinoid receptor biology. -
CB1 Antagonist
ABD459 is a selective CB1 receptor antagonist that plays a crucial role in modulating food intake and sleep-wake cycles. It effectively displaces the CB1 agonist CP99540 with a Ki value of 8.6 nM and antagonizes CP55940-induced GTPγS binding, exhibiting a KB value of 7.7 nM. This compound may influence endogenous cannabinoid release via cholinergic activity and is relevant for research focused on neurological disorders and attentional processes. -
CB1 Receptor Antagonist
CB1 Antagonist 5 is a selective antagonist of the cannabinoid receptor type 1 (CB1), exhibiting a Ki value of 243 nM alongside an EC50 of 195 nM. This compound is valuable for research applications targeting the endocannabinoid system and may assist in studies related to pain modulation, appetite regulation, and neuroprotection. Its specificity for the CB1 receptor makes it an essential tool for exploring the physiological roles and therapeutic potentials of cannabinoid signaling. -
Cannabinoid
(-)-11-Hydroxy-Δ8-tetrahydrocannabivarin is a synthetic cannabinoid that primarily targets cannabinoid receptors. It exhibits biological activities related to modulation of the endocannabinoid system, making it suitable for research into therapeutic applications in pain relief, appetite regulation, and neurological disorders. This compound is valuable for studies focused on the pharmacological effects of cannabinoids and their potential medicinal uses. -
Phytocannabinoid Derivative
exo-Tetrahydrocannabivarin methyl ether is a phytocannabinoid derivative that interacts with cannabinoid receptors in the endocannabinoid system. This compound exhibits potential analgesic and anti-inflammatory properties, making it a valuable tool for research in pain management and inflammation studies. Its structural similarity to other phytocannabinoids allows for comparative studies on cannabinoid activity and therapeutic applications. -
Phytocannabinoid Derivative
10(S)-Hydroxy-9(R)-hexahydrocannabinol is a phytocannabinoid derivative known for its interactions with cannabinoid receptors. This compound exhibits biological activity that may influence neuroprotective and analgesic pathways. It is useful in research studies focused on the endocannabinoid system, offering insights into the pharmacological properties of cannabinoids in therapeutic contexts. -
Phytocannabinoid Derivative
Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is a phytocannabinoid derivative that exerts its effects primarily through cannabinoid receptors in the endocannabinoid system. This compound is of significant interest for research into its potential therapeutic effects, including anxiolytic and analgesic properties. It is utilized in studies investigating the biological mechanisms of cannabinoids and their implications in various neurological and physiological processes. -
Cannabinoid Derivative
Cannabigerophorol (CBGP) is a cannabinoid derivative that acts on the cannabinoid receptors in the endocannabinoid system. This compound exhibits notable biological activity, including potential analgesic and anti-inflammatory effects. Researchers utilize CBGP to explore its therapeutic applications in pain management, neuroprotection, and other conditions influenced by the endocannabinoid system. -
Ether Analogs of Cannabinoids
8β-Hydroxy-exo-THC is a cannabinoid ether analog that primarily targets cannabinoid receptors. This compound exhibits a modest receptor affinity, with an IC50 value of 1.2 μM. It is utilized in research to explore the pharmacological properties of cannabinoid derivatives and their potential therapeutic applications. -
Cannabinoid
ADB-BINACA is a synthetic cannabinoid that targets the cannabinoid receptors in the endocannabinoid system. It exhibits potent agonistic activity at both CB1 and CB2 receptors, making it useful in the exploration of cannabinoid signaling pathways. This compound is often utilized in pharmacological studies and research related to cannabinoid-based therapies and neurological disorders. -
Phytocannabinoid Derivative
Δ8-THCBA-A is a phytocannabinoid derivative that functions as a selective modulator of cannabinoid receptors. It exhibits notable biological activity by influencing cannabinoid signaling pathways, making it valuable for research in the fields of neuropharmacology and cannabinoid pharmacology. Its unique structural properties and receptor interactions facilitate the exploration of therapeutic applications related to cannabinoid-based treatments. -
Cannabinoid Receptor
Arachidonoyl-N,N-dimethyl amide targets cannabinoid receptors with reduced binding affinity for the human central cannabinoid (CB1) receptor (Ki >1 μM). This analog of anandamide demonstrates significant biological activity by completely inhibiting rat glial gap junction communication at a concentration of 50 μM. Its unique properties make it a valuable tool for investigating cannabinoid signaling and understanding the role of endocannabinoids in neurological functions. -
Cannabinoid Receptor
6α-Oxycodol N-oxide is an opioid derivative that primarily targets the cannabinoid receptor. As a metabolite of Oxycodone, it exhibits potential biological activity relevant to pain modulation and cannabinoid signaling pathways. This compound is useful for research applications focused on opioid-cannabinoid interactions and the investigation of analgesic mechanisms. -
GPR55 Fluorescent Ligand
Tocrifluor 1117 is a selective fluorescent ligand targeting the GPR55 receptor. This compound serves as a valuable tool in research for visualizing the cellular distribution of cannabinoid receptors, including GPR55, in live tissues. With excitation and emission maxima at 543 nm and 590 nm, respectively, Tocrifluor 1117 enhances the understanding of cannabinoid receptor localization and function in various biological contexts. -
Phytocannabinoid Derivative
Hexocannabitriol is a phytocannabinoid derivative that interacts with the endocannabinoid system, primarily targeting cannabinoid receptors. Its structural similarity to other phytocannabinoids suggests potential for modulating various physiological processes, including pain relief and anti-inflammatory effects. This compound is suitable for research applications investigating cannabinoid receptor signaling pathways and the therapeutic effects of cannabinoids in various biological models. -
Cannabinoid Receptor
Cannabinol methyl ether primarily targets the cannabinoid receptors in the body. This compound exhibits potential biological activity related to modulation of cannabinoid signaling pathways. Its applications in research include the study of cannabis-derived compounds in therapeutic contexts and the exploration of their effects on various physiological processes. -
Cannabinoid Receptor
Cannabigerovarin is a phytocannabinoid that primarily targets cannabinoid receptors. It exhibits significant biological activity in modulating the endocannabinoid system, making it valuable for research in cannabinoid pharmacology and its potential therapeutic applications. This compound is suitable for various scientific investigations, including studies on the effects of cannabinoids in both preclinical and forensic contexts. -
Cannabinoid
PTI-1 is a synthetic cannabinoid that targets cannabinoid receptors, exhibiting efficacy in modulating the endocannabinoid system. It is primarily used in research to explore the therapeutic potential of cannabinoids in various neurological and inflammatory conditions. The compound's ability to mimic endogenous cannabinoids makes it a valuable tool for studying receptor activation and downstream signaling pathways. -
Analog of Phytocannabinoids
Δ8-THCB (∆8-Tetrahydrocannabutol) is an analog of phytocannabinoids, specifically related to Δ8-tetrahydrocannabinol. This compound exhibits significant activity at cannabinoid receptors, which contributes to its potential therapeutic benefits. Δ8-THCB is primarily utilized in research focused on cannabinoid signaling pathways and pharmacological studies related to the endocannabinoid system. -
Phytocannabinoid Derivative
11-Nor-9(S)-carboxy-hexahydrocannabinol is a phytocannabinoid derivative that displays significant interaction with the endocannabinoid system, primarily through modulation of cannabinoid receptors. This compound exhibits potential anti-inflammatory and analgesic effects, making it valuable for research in pain management and neuroprotection. Its structural similarity to known phytocannabinoids allows for comparative studies in cannabinoid pharmacology and therapeutic applications. -
Endocannabinoid
Tricosanoyl ethanolamide is an endocannabinoid that derives from ethanolamine and tricosanoic acid, featuring a unique 23-carbon chain. This compound engages with endocannabinoid receptors and plays a crucial role in modulating various physiological processes. Tricosanoyl ethanolamide is valuable for research into diseases linked to the endocannabinoid system, providing insights into its potential therapeutic applications. -
Phytocannabinoid Derivative
Cannabinol acetate, a phytocannabinoid derivative, is structurally related to recognized phytocannabinoids. This compound has been studied for its potential pharmacological effects, particularly in modulating cannabinoid receptors. Its research applications include investigations into neuroprotection, analgesia, and potential therapeutic benefits in various ailments associated with the endocannabinoid system. -
Cannabinoid Receptor
Cannabinol ethyl (CBN-C2) acts as a cannabinoid receptor agonist, engaging with the endocannabinoid system to modulate various physiological processes. It exhibits notable anti-inflammatory and analgesic properties, making it valuable for research into pain management and neurological disorders. This compound provides a useful tool for studying cannabinoid receptor pathways and their implications in health and disease.
